Skip to main content

Table 4 Association between CYP2C19*2, *3, PON1 Q192R and clopidogrel resistance

From: The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention

Genotype

Crude OR(95%CL)

P value

Adjusted OR

(95%CL)

P value

CYP2C19*2(GG)

1

 

1

 

CYP2C19*2(GA)

2.81(1.12–6.59)

0.018

2.99(1.11–8.03)

0.03

CYP2C19*2(AA)

12.47(3.77–41.22)

< 0.001

8.62(2.29–32.46)

0.001

CYP2C19*3(GG)

1

 

1

 

CYP2C19*3(GA)

5.31(1.96–14.41)

< 0.001

3.64(0.98–13.56)

0.054

1*/1*

1

 

1

 

1*/2*

4.41(1.35–14.41)

0.14

6.65(1.77–25.04)

0.005

1*/3*

10.89(2.36–50.30)

0.002

22.74(3.11–166.27)

0.002

2*/2*

27.96(6.77–115.52)

< 0.001

48.49(8.16–287.97)

< 0.001

2*/3*

106.75(10.42–1093.57)

< 0.001

241.32(14.59–3991.37)

< 0.001

PON1(Q192R)QQ(AA)

1

 

1

 

PON1(Q192R)QR(AG)

2.68(0.56–12.90)

0.22

3.01(0.53–17.05)

0.213

PON1(Q192R)RR(GG)

5.47(1.19–25.23)

0.029

5.69(1.06–30.47)

0.042

  1. p < 0.05: Risk is statistical significant when compared to the reference genotype